Abstract
Purpose: Tetomilast, an anti-inflammatory compound, is being developed for the treatment of inflammatory bowel disease (IBD). Although its mechanism of action has not been fully elucidated, it is known to inhibit phosphodiesterase 4 (PDE4) activity. To investigate the mechanisms involved in tetomilast's anti-inflammatory action, we compared its effects on CD4 T cells, which have been associated with the pathogenesis of IBD, with that of several known PDE4 inhibitors. Methods: The effect of tetomilast on recombinant human PDE4 subtypes was determined by PDE assay. IC50 was calculated from dose-response curves for tetomilast and for the PDE4 inhibitors cilomilast, rolipram, and roflumilast. Human CD4 T cells were purified from the blood of healthy donors using a commercial CD4 T cell isolation kit. CD4 T cells were stimulated using anti-CD3 and anti-CD28 antibodies and incubated in the absence or presence of test compounds for 72 hr at 37°C. For determination of T cell proliferation, [3H]-thymidine (0.2 μCi/well) was added for the last 18 hr of the incubation period. Interferon-γ (INF-γ) released into the culture medium was determined by ELISA. Results: Tetomilast was found to be a potent inhibitor of PDE4 subtypes. Its selectivity for inhibiting the high-affinity rolipram-binding (HARB) conformer of PDE4 was reduced compared with that of rolipram. Tetomilast's PDE4 inhibitory potency was similar to that of rolipram and cilomilast and was at least 100× less than that of roflumilast. At 10 μM, tetomilast caused a significantly greater inhibition of CD3/CD28-stimulated T cell proliferation than did the equivalent PDE4-inhibitory concentrations of 10 μM cilomilast, 10 μM rolipram, and 0.1 μM roflumilast. Tetomilast also demonstrated greater inhibition of INF-γ release from CD3/CD28-stimulated T cells as compared with the other PDE4 inhibitors. Conclusions: Compared with rolipram, tetomilast showed a reduced selectivity for inhibition of the HARB conformer of PDE4, predicting a reduction in side effects, which have been associated with binding of PDE4 inhibitors to the HARB site in the CNS and gastrointestinal tract. Tetomilast's inhibition of CD3/CD28-stimulated CD4 T cell proliferation and INF-γ release was significantly greater than that of the other PDE4 inhibitors tested, suggesting that other mechanisms beyond PDE4 inhibition may account for the pharmacologic activity of tetomilast.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have